Cancer-Fighting immune cells from donors tested in new leukemia treatment
NCT ID NCT05834244
Summary
This early-stage trial is testing whether adding a healthy donor's natural killer (NK) immune cells to two standard leukemia drugs can help control acute myeloid leukemia (AML). The study will enroll 32 adults with AML that has returned or not responded to prior treatment, or older adults newly diagnosed with high-risk AML. The main goal is to check the safety of this three-part combination and see if it helps patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Western Reserve University
RECRUITINGCleveland, Ohio, 44106, United States
Contact Email: •••••@•••••
Contact
-
M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.